Combined Hyperlipidemias Polygenic Risk Score

Some people develop high cholesterol and high triglycerides together, and that combination drives heart attacks at rates close to people born with classic familial high cholesterol. The frustrating part is that most of these cases are not caused by a single faulty gene. They are written into many small DNA variants spread across your genome, and a routine lipid panel cannot tell you whether you carry that inherited load.

This score, called CHL PRS (Combined Hyperlipidemias Polygenic Risk Score), reads those variants from a one-time DNA sample and turns them into a number that reflects your lifelong genetic pressure toward mixed dyslipidemia. It does not measure lipids in your blood today. It tells you how strongly your biology is set up to push them in the wrong direction over decades.

What This Score Actually Measures

A polygenic risk score is not a hormone or a protein. It is a weighted sum of many single-letter DNA differences (called SNPs) that have been linked in large genetic studies to higher LDL cholesterol and triglycerides. Each variant nudges your lipid biology by a tiny amount. The score adds those nudges together to estimate your inherited starting position.

Combined hyperlipidemia, sometimes called familial combined hyperlipidemia (FCHL), turns out to be largely polygenic rather than caused by one inherited gene. In families with classic FCHL, only about 3% of affected relatives carry a single high-impact mutation, while roughly 35% sit above the 90th percentile for an LDL or triglyceride polygenic score. In one population analysis, combined hyperlipidemia showed about 54% genetic heritability tied to common variants, meaning more than half of the variation between people traces back to inherited DNA.

Because your DNA does not change with diet, age, or medication, this score reflects a stable underlying tendency. It is the genetic floor your lipids are building on, separate from your current lab readings.

Heart Disease Risk

The strongest evidence for this score sits in coronary artery disease, which is the medical name for the narrowing of arteries that causes heart attacks. The combined hyperlipidemia phenotype is one of the highest-risk lipid patterns identified in large biobanks.

In a UK Biobank analysis of 450,636 adults followed for a median of 11 years, people classified as having combined hyperlipidemia had about 1.9 times the risk of a future coronary event compared with people who had normal lipids (HR 1.92, 95% CI 1.84 to 2.01). When researchers further adjusted for non-HDL cholesterol, the combined pattern still carried about 45% extra hazard (HR 1.45, 95% CI 1.30 to 1.60). That residual risk is the part a standard lipid panel misses.

A separate analysis of UK Biobank participants compared people with a high polygenic load to people with monogenic familial hypercholesterolemia. Those with a polygenic FCHL pattern had about 2.7 times the risk of coronary artery disease versus controls, compared with 1.9 times for monogenic FH carriers, even though the polygenic pattern is roughly five times more common. The genetic mechanism is different, but the heart attack risk is similar.

In a Finnish cohort of 135,638 adults, the top 5% of an LDL cholesterol polygenic score had about 36% higher odds of coronary artery disease than the rest of the population (OR 1.36, 95% CI 1.24 to 1.49). The triglyceride polygenic score showed a similar pattern (OR 1.31, 95% CI 1.19 to 1.43).

Recurrent Stroke and Cholesterol Control

Stroke survivors with a high polygenic susceptibility to hyperlipidemia have a noticeably harder time getting their cholesterol under control and a higher rate of new vascular events. In a study of 1,567 ischemic stroke survivors, people in the top 20% of the score had about 2.1 times the rate of recurrent stroke (HR 2.12, 95% CI 1.19 to 3.78) and about 1.9 times the rate of acute coronary events (HR 1.87, 95% CI 1.21 to 2.87) compared with those in the bottom 20%.

The same group had about 66% higher odds of uncontrolled hyperlipidemia on standard therapy (OR 1.66, 95% CI 1.17 to 2.35). A replication analysis in 1,634 UK Biobank stroke survivors showed the same pattern, with the high-score group more than twice as likely to have uncontrolled or resistant hyperlipidemia. The score appears to flag people whose biology pushes back hard against lifestyle and standard doses of medication.

Type 2 Diabetes and Chronic Kidney Disease

Lipid polygenic scores also track with broader cardiometabolic risk. In a large Korean cohort, a triglyceride-related polygenic score was associated with higher risk of incident chronic kidney disease. East Asian polygenic scores combining lipid variants improved prediction of future hyperlipidemia and coronary heart disease in people with type 2 diabetes, beyond age, sex, and standard risk factors. These signals are real but smaller than the coronary artery disease association, and they are most useful as part of a broader risk picture.

What the Score Does Not Replace

This is a research-grade marker. Standardized clinical thresholds do not exist yet, and the score performs less accurately in non-European ancestries because most of the original genetic studies were done in European populations. Its predictive lift over traditional risk factors is modest in middle age, and most strongly useful earlier in life when most other risk factors have not yet declared themselves.

Two findings can seem to contradict each other. A high score does not mean you will definitely develop heart disease, and a normal lipid panel today does not mean your score is low. Think of this measurement as the wind direction, not the weather. The score tells you which way your biology is pushing across decades. Your current LDL, triglycerides, ApoB, and Lp(a) measure today's weather. You need both.

Why One Reading Is Enough, But Trending Matters Around It

The polygenic score itself is set at conception and does not change. You only need to measure it once in your life. What changes around it is everything the score predicts: your lipid panel, your ApoB, your blood pressure, your kidney function, and your coronary calcium. Those are the numbers you should be tracking over time, especially if your score comes back high.

A reasonable rhythm for someone with a high score is a baseline full lipid workup including ApoB and Lp(a), a repeat in 3 to 6 months after any changes to diet or therapy, and an annual lipid and metabolic panel after that. People in the highest polygenic risk group may also benefit from earlier imaging, such as a coronary calcium scan in their 40s rather than waiting until their 50s or 60s.

What to Do With an Out-of-Pattern Result

If your score lands in the upper end and your current lipids look fine, do not assume you are in the clear. Lipid panels can look reassuring in your 30s and 40s while inherited risk silently builds plaque. The next steps are to confirm ApoB and Lp(a), get a full lipid panel including non-HDL cholesterol, check fasting glucose and HbA1c since combined hyperlipidemia clusters with insulin resistance, and consider a coronary artery calcium scan if you are over 40. A consultation with a lipidologist or preventive cardiologist is worth it if your score is in the top tenth and you have any family history of early heart disease.

If your score is low but your lipids are clearly abnormal, the picture flips. Severely high LDL with a low polygenic score points toward a possible single-gene cause such as familial hypercholesterolemia, which deserves its own targeted genetic testing and family screening. Lp(a) is a separate inherited trait not captured by this score, and it should be checked at least once regardless of where your polygenic risk falls.

When Results Can Be Misleading

A few situations can make this score harder to interpret correctly:

• Ancestry mismatch: the score was developed mostly in European populations and is less accurate in people of African, East Asian, South Asian, or mixed ancestry. A result in those groups should be interpreted with extra caution.
• Lp(a) and monogenic FH: these are separate inherited lipid risks that this score does not measure. A low polygenic score does not rule them out.
• Body weight and metabolic syndrome: these strongly amplify the lipid impact of a high score. Two people with the same genetic load can have very different triglyceride levels depending on body fat and insulin sensitivity.
• Current lipid-lowering therapy: statins or fibrates change your measured lipids but not your score. The score still reflects your underlying inherited risk even if your current LDL looks well controlled.